Delivering a high degree of sensitivity for HCC detection

Learn more about our performance and clinical trials

Robustly designed for early detection of HCC in real-world settings

The Oncoguard® Liver test was designed to deliver a high level of accuracy with enhanced sensitivity for detection of early-stage HCC.1



At 87% specificity, the Oncoguard® Liver test demonstrates:

82 percent sensitivity
94 percent sensitivity

Validation of the test demonstrated high performance compared with:

AFP vs Oncoguard Liver

Ongoing clinical trials

icon-add-account-onLearn more about the clinical trials the Oncoguard® Liver solution is currently engaged in.

Localized stage



Five-year survival rate for those who are diagnosed at an early stage and undergo curative therapy

Regional stage

Distant stage



Five-year survival rate for those diagnosed at late stage2


The strong performance of the Oncoguard® Liver test combined with easy-to-interpret results may enable early-stage HCC detection—a fundamental step toward improving outcomes for patients.1

References: 1. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021), doi: https:// 2. Liver cancer survival rates. American Cancer Society. Revised January 29, 2021. Accessed March 23, 2021.